AbbVie (NYSE:ABBV) is scheduled to announce Q4 earnings results on Friday, January 31st, before market open. Analysts expect ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, showcasing resilience and growth. AbbVie's diversified product categories ...